Clinical trial
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential…
NCT00430508 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00430508 |
|---|---|
| Title | Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension |
| Official title | Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy |
| Lead sponsor | Daiichi Sankyo, Industry |
| Collaborators | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo, olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil/hydrochlorothiazide tablets |
| Enrollment | 972 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Jan 9, 2019 |
| Countries | Bulgaria, Czechia, France, Germany, Poland, Spain, Ukraine |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: